Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Conditions:   Relapsed Angioimmunoblastic T-Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma Interventions:   Drug: Oral azacitidine;   Drug: Romidepsin;   Drug: Bendamustine;   Drug: Gemcitabine Sponsors:   The Lymphoma Academic Research Organisation;   Celgene Not yet recruiting

Source: ClinicalTrials.gov - July 19, 2018 Category: Research Source Type: clinical trials